Impax Laboratories Inc  

(Public, NASDAQ:IPXL)   Watch this stock  
Find more results for IMPAX Laboratories, Inc.�
+1.91 (5.26%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.00 - 38.24
52 week 23.31 - 52.10
Open 35.00
Vol / Avg. 0.00/1.01M
Mkt cap 2.76B
P/E 361.43
Div/yield     -
EPS 0.11
Shares 71.79M
Beta 1.32
Inst. own 99%
Nov 9, 2015
Q3 2015 Impax Laboratories Inc Earnings Call - 8:30AM EST - Add to calendar
Nov 9, 2015
Q3 2015 Impax Laboratories Inc Earnings Release Add to calendar
Sep 18, 2015
Impax Laboratories Inc at Morgan Stanley Healthcare Conference
Sep 8, 2015
Impax Laboratories Inc Announces Resolution of FDA Warning Letter Related to its Hayward Manufacturing Facility Conference Call
Aug 10, 2015
Q2 2015 Impax Laboratories Inc Earnings Release
Aug 10, 2015
Q2 2015 Impax Laboratories Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -0.86% 9.62%
Operating margin 0.54% 14.90%
EBITD margin - 21.99%
Return on average assets -0.39% 5.53%
Return on average equity -0.79% 6.76%
Employees 1,061 -
CDP Score - -


30831 Huntwood Ave
HAYWARD, CA 94544-7003
United States - Map
+1-510-2406000 (Phone)
+1-510-4713200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. The Company operates in two segments: Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma is engaged in the development of brand pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Impax Specialty Pharma is also engaged in the sale and distribution of Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.

Officers and directors

Robert L. Burr Independent Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
G. Frederick Wilkinson President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Bryan M. Reasons Chief Financial Officer, Senior Vice President - Finance
Age: 47
Bio & Compensation  - Reuters
Michael J. Nestor President - Impax Pharmaceutical Division
Age: 62
Bio & Compensation  - Reuters
Deborah Penza Senior Vice President, Chief Compliance Officer
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Senior Vice President, General Counsel, Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Donna M. Hughes Senior Vice President of Human Resources
Bio & Compensation  - Reuters
Jeffrey D Nornhold Senior Vice President - Technical Operations
Age: 49
Bio & Compensation  - Reuters
Leslie Z. Benet Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Allen Chao Ph.D Independent Director
Age: 69
Bio & Compensation  - Reuters